• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Alector to Participate in Upcoming Healthcare Conferences

    5/6/25 8:00:00 AM ET
    $ALEC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $ALEC alert in real time by email

    SOUTH SAN FRANCISCO, Calif., May 06, 2025 (GLOBE NEWSWIRE) -- Alector, Inc. (NASDAQ:ALEC), a late-stage clinical biotechnology company focused on developing therapies to counteract the devastating progression of neurodegeneration, today announced that management will participate in the following upcoming investor conferences:

    • Bank of America Securities Health Care Conference (Las Vegas, Nevada)
      • Tuesday, May 13, 2025, at 2:20 p.m. PT, corporate presentation
    • H.C. Wainwright 3rd Annual BioConnect Investor Conference (New York, New York)
      • Tuesday, May 20, 2025, at 12:00 p.m. ET, fireside chat

    A webcast of each conference presentation will be available on the "Events & Presentations" page within the Investors section of the Alector website at http://investors.alector.com. Replays of the webcasts will be available on the Alector website for 90 days following the presentation dates.

    About Alector

    Alector is a late-stage clinical biotechnology company focused on developing therapies to counteract the devastating progression of neurodegenerative diseases. Leveraging the principles of genetics, immunology, and neuroscience, the company is advancing a portfolio of genetically validated programs that aim to remove toxic proteins, replace deficient proteins, and restore immune and nerve cell function. Supported by biomarkers, Alector's product candidates seek to treat a range of indications, such as frontotemporal dementia, Alzheimer's disease, and Parkinson's disease. The company is also developing Alector Brain Carrier (ABC), a proprietary blood-brain barrier platform, which is being selectively applied to its next-generation product candidates and research pipeline. ABC aims to enhance the delivery of therapeutics, achieve deeper brain penetration and efficacy at lower doses, and ultimately improve patient outcomes while reducing costs. Alector is headquartered in South San Francisco, California. For more information, please visit www.alector.com.

    Alector Contacts:

    Alector

    Katie Hogan

    202-549-0557

    [email protected]

    Argot Partners (media)

    David Rosen

    646-461-6387

    [email protected]

    Argot Partners (investors)

    Laura Perry

    212-600-1902

    [email protected]



    Primary Logo

    Get the next $ALEC alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ALEC

    DatePrice TargetRatingAnalyst
    12/17/2024$9.00 → $2.50Outperform → Neutral
    Mizuho
    12/16/2024$4.00Buy → Hold
    Stifel
    12/4/2024$9.00 → $1.00Neutral → Underperform
    BofA Securities
    11/29/2024$35.00 → $7.00Buy
    H.C. Wainwright
    11/26/2024$10.00 → $3.00Equal-Weight → Underweight
    Morgan Stanley
    12/14/2023$8.00 → $15.00Hold → Buy
    Stifel
    12/12/2023$12.00Buy
    Deutsche Bank
    9/25/2023$4.00Sell
    Goldman
    More analyst ratings

    $ALEC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Yaffe Kristine was granted 28,700 shares, increasing direct ownership by 42% to 96,409 units (SEC Form 4)

      4 - Alector, Inc. (0001653087) (Issuer)

      6/12/25 6:05:19 PM ET
      $ALEC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Director Garofalo Elizabeth A. was granted 28,700 shares, increasing direct ownership by 47% to 89,950 units (SEC Form 4)

      4 - Alector, Inc. (0001653087) (Issuer)

      6/12/25 6:05:09 PM ET
      $ALEC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Director Hammond Paula was granted 28,700 shares, increasing direct ownership by 48% to 88,909 units (SEC Form 4)

      4 - Alector, Inc. (0001653087) (Issuer)

      6/12/25 6:05:20 PM ET
      $ALEC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care